Bienvenu(e) sur le site de l'Institut Necker Enfants Malades
Mercredi 31 janvier 2024
New Marker for Cardiovascular Risk in Type 2 Diabetes Patients – Our researchers in the spotlight

A novel prognostic marker for cardiovascular risk in individuals with type 2 diabetes (T2D) has been identified by the IMMEDIAB team – Immunity and Metabolism in Diabetes, led by Nicolas Venteclef at INEM.

This breakthrough, the result of collective and collaborative efforts, positions our researchers at the forefront of a significant scientific leap.

The study, involving phenotypic, transcriptomic, and metabolomic analyses across three cohorts of T2D patients - Angiosafe, GLUTADIAB, and SURDIAGENE - reveals a correlation between the number of circulating monocytes and an increased risk of cardiovascular events such as stroke or myocardial infarction over a decade.

Published in Circulation Research and highlighted in an INSERM press release, this work is a substantial step forward in understanding, assessing, and preventing cardiovascular incidents in type 2 diabetic patients.

With a patent already filed for this discovery and the ongoing development of a cutting-edge electronic sensor for measuring circulating monocytes from a single drop of blood, this innovation promises to transform patient care.

The potential impact of this research on the cardiovascular health of millions of people with type 2 diabetes is immense, ushering in new and promising horizons in the medical field.

To read the press release: inserm press

To learn more about the study: Circulation Research

Adresse

Notice: Undefined variable: contact_addr in /homepages/40/d483507699/htdocs/location.php on line 21
Parrain(s)
S.A.R. la Princesse Caroline de Hanovre qui, à travers la Fondation Princesse Grace, soutient déjà la recherche medicale et tout ce qui contribue à soulager les enfants malades en France et dans le monde, a accepté de s'engager à nos cotés pour que ce centre de medecine moleculaire, tourné entre autres vers les pathologies des enfants, prenne de vitesse les maladies et continue à relever les defis actuels.

INEM - Organigramme